Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year


Summary for Tradename: SANDOSTATIN LAR

Suppliers: see list1
2013 Sales:$697,961,000
patent expirations by year for

Clinical Trials for: SANDOSTATIN LAR

Ultrasound Guided Sandostatin LAR Injection in Acromegaly
Status: Recruiting Condition: Acromegaly

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Status: Completed Condition: Acromegaly

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Status: Completed Condition: Peritoneal Neoplasms; Intestinal Obstruction; Carcinomatosis

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Status: Active, not recruiting Condition: Neuroendocrine Carcinoma; Neuroendocrine

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Status: Completed Condition: Neuroendocrine Carcinoma; Islet Cell Carcinoma

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
Status: Completed Condition: Cirrhosis; Portal Hypertension; Esophageal Varices

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Status: Completed Condition: Chemotherapy-induced Diarrhea

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Status: Completed Condition: Carcinoid Tumor; Malignant Carcinoid Syndrome

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
Status: Completed Condition: Acromegaly

Effects of Sandostatin LARĀ® in Acromegaly
Status: Active, not recruiting Condition: Acromegaly

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
octreotide acetate
INJECTABLE;INJECTION021008Nov 25, 1998RXNo5,538,739*PED<disabled>Y<disabled>
octreotide acetate
INJECTABLE;INJECTION021008Nov 25, 1998RXNo5,639,480*PED<disabled>Y<disabled>
octreotide acetate
INJECTABLE;INJECTION021008Nov 25, 1998RXNo5,688,530*PED<disabled>Y<disabled>
octreotide acetate
INJECTABLE;INJECTION021008Nov 25, 1998RXNo5,922,338*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology